Resource Summary Report

Generated by NIF on Sep 17, 2026

LS180

RRID:CVCL_0397
Type: Cell Line

Proper Citation

RRID:CVCL_0397

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0397

Proper Citation: RRID:CVCL_0397

Description: Cell line LS180 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Colon adenocarcinoma

Defining Citation: PMID:1262041, PMID:6652615, PMID:7370982, PMID:9515795, PMID:10737795, PMID:11314036, PMID:12615714, PMID:16418264, PMID:18258742, PMID:20215515, PMID:20570890, PMID:20606684, PMID:22460905, PMID:23272949, PMID:24755471, PMID:25485619, PMID:25877200, PMID:25926053, PMID:26537799, PMID:26589293, PMID:27397505, PMID:28854368, PMID:29101300, PMID:29444439, PMID:30894373, PMID:30971826, PMID:31068700, PMID:31978347, PMID:35839778

Comments: Population: Caucasian., Part of: RAS genetic alteration cell panel (ATCC TCP-1031)., Part of: NCI RAS program mutant KRAS cell line panel., Part of: KuDOS 95 cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Part of: AstraZeneca Colorectal cell line (AZCL) panel., Group: Patented cell line.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: LS180

Synonyms: LS-180, LS 180, Laboratory of Surgery 180

Cross References: BTO:BTO_0001609, CLO:CLO_0007394, CLO:CLO_0007404, EFO:EFO_0006640, MCCL:MCC:0000291, CLDB:cl3262, CLDB:cl3263, CLDB:cl7120,

AddexBio:C0009006/56, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CCL-187, ATCC:CL-187, BCRC:60100, BioGRID_ORCS_Cell_line:564, BioSample:SAMN03472231, BioSample:SAMN10988327, cancercelllines:CVCL_0397, CCRID:1101HUM-PUMC000284, Cell_Model_Passport:SIDM00680, ChEMBL-Cells:CHEMBL4295398, ChEMBL-Targets:CHEMBL4296462, CLS:305823, ColonAtlas:LS180, Cosmic:869793, Cosmic:913893, Cosmic:948854, Cosmic:995378, Cosmic:1043820, Cosmic:1184098, Cosmic:1187311, Cosmic:1466819, Cosmic:1479574, Cosmic:1708417, Cosmic:2052595, Cosmic:2301998, Cosmic:2667976, Cosmic:2727472, Cosmic-CLP:998189, DepMap:ACH-000957, ECACC:87021202, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:998189, GEO:GSM206520, GEO:GSM513928, GEO:GSM514299, GEO:GSM741271, GEO:GSM784017, GEO:GSM827346, GEO:GSM887279, GEO:GSM888354, GEO:GSM1346847, GEO:GSM1374634, GEO:GSM1374635, GEO:GSM1374636, GEO:GSM1448139, GEO:GSM1670060, IARC_TP53:21766, ICLC:HTL01016, IZSLER:BS TCL 82, LiGeA:CCLE_023, LINCS_LDP:LCL-1183, Lonza:348, MetaboLights:MTBLS227, NCBI_Iran:C508, PharmacoDB:LS180_859_2019, PRIDE:PXD005235, PRIDE:PXD005354, PRIDE:PXD005355, PRIDE:PXD030304, Progenetix:CVCL_0397, PubChem_Cell_line:CVCL_0397, Wikidata:Q54903057

ID: CVCL_0397

Record Creation Time: 20220427T220735+0000

Record Last Update: 20260913T004755+0000

Ratings and Alerts

No rating or validation information has been found for LS180.

Warning: Discontinued: ATCC; CCL-187
Population: Caucasian., Part of: RAS genetic alteration cell panel (ATCC TCP-1031)., Part of: NCI RAS program mutant KRAS cell line panel., Part of: KuDOS 95 cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Part of: AstraZeneca Colorectal cell line (AZCL) panel., Group: Patented cell line.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 129 mentions in open access literature.

Listed below are recent publications. The full list is available at NIF .

Zhang Y, et al. (2026) Paneth-like transition drives resistance to dual targeting of KRAS and EGFR in colorectal cancer. Cancer cell, 44(1), 77.

Sorrenti E, et al. (2026) Intratumoral microbiota and host genotype cooperatively shape neutrophil cytotoxic functions in colorectal cancer. Cell host & microbe, 34(3), 425.

Liang J, et al. (2026) DHODH is a synthetic lethal target in PIK3CA-mutant colorectal cancer. Cell reports, 45(8), 117719.

Domagalski M, et al. (2026) Visceral and subcutaneous adipose stem cells modulate colorectal cancer cell progression: direct and indirect contact distinctly accelerate tumor aggressiveness. Molecular medicine (Cambridge, Mass.), 32(1).

Choi PH, et al. (2026) Distinct ERK and PI3K dependencies mediate a heterogeneous response to RAS(ON) inhibition in KRAS-mutant colorectal cancer. Cell reports, 45(7), 117559.

Jacob J, et al. (2025) Antibody-Drug Conjugates Targeting the EGFR Ligand Epiregulin Elicit Robust Antitumor Activity in Colorectal Cancer. Cancer research, 85(5), 973.

Wolf G, et al. (2025) The efflux pump ABCC1/MRP1 constitutively restricts PROTAC sensitivity in cancer cells. Cell chemical biology, 32(2), 291.

Clarkson E, et al. (2025) BMP antagonist CHRDL2 enhances the cancer stem-cell phenotype and increases chemotherapy resistance in colorectal cancer. Molecular oncology, 19(11), 3135.

Zhang C, et al. (2025) Targeting WEE1 in ARID1A/TP53 Concurrent Mutant Colorectal Cancer by Exploiting R-Loop Accumulation and DNA Repair Deficiencies. Advanced science (Weinheim, Baden-Wurttemberg, Germany), e12074.

Wiedmer T, et al. (2025) Metabolic mapping of the human solute carrier superfamily. Molecular systems biology, 21(6), 560.

Baglamis S, et al. (2025) Clonal dispersal is associated with tumor heterogeneity and poor prognosis in colorectal cancer. iScience, 28(5), 112403.

Castro J, et al. (2025) A Potent, Selective, Small-Molecule Inhibitor of DHX9 Abrogates Proliferation of Microsatellite Instable Cancers with Deficient Mismatch Repair. Cancer research, 85(4), 758.

Suzuki H, et al. (2025) GALNT7 Stratifies dMMR/MSI Colorectal Cancer into Distinct Molecular Subsets Associated with Prognosis and PD-L1 Expression. Cancer research communications, 5(9), 1530.

Feng J, et al. (2025) A pan-KRAS inhibitor and its derived degrader elicit multifaceted anti-tumor efficacy in KRAS-driven cancers. Cancer cell.

Likasitwatanakul P, et al. (2025) Chemical Perturbations Impacting Histone Acetylation Govern Colorectal Cancer Differentiation. Gastroenterology.

Frommelt F, et al. (2025) The solute carrier superfamily interactome. Molecular systems biology, 21(6), 632.

Cook AL, et al. (2025) Identification of nonsense-mediated decay inhibitors that alter the tumor immune landscape. eLife, 13.

Jacob J, et al. (2024) Antibody-Drug Conjugates Targeting the EGFR Ligand Epiregulin Elicit Robust Anti-Tumor Activity in Colorectal Cancer. bioRxiv : the preprint server for biology.

Bootsma S, et al. (2024) Exploiting a subtype-specific mitochondrial vulnerability for successful treatment of colorectal peritoneal metastases. Cell reports. Medicine, 5(5), 101523.

Pacini C, et al. (2024) A comprehensive clinically informed map of dependencies in cancer cells and framework for target prioritization. Cancer cell, 42(2), 301.